Literature DB >> 21504362

HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy.

María del Palacio Tamarit1, Carmen Quereda, Marta Gonzalez-Rozas, Iñigo Corral, José L Casado.   

Abstract

HIV-1 viral encephalitis produced by antiretroviral-resistant strains in cerebrospinal fluid (CSF), despite suppression of plasma HIV-1 RNA, has been rarely described. We report two cases of symptomatic viral encephalitis demonstrated by clinical, magnetic resonance imaging (MRI), and an inflammatory CSF profile. Viral load in CSF was 24,000 and 6850 copies/ml, whereas plasma HIV RNA level was undetectable since the beginning of therapy. A resistance test in CSF showed genotypic mutations confering resistance to the drugs the patients received for more than 2 years. In the two cases, a high baseline HIV RNA level, a low nadir CD4(+) count, and suboptimal CSF levels of atazanavir were considered as the risk factors for developing encephalitis. The two cases did not resolve with a change to antiretroviral drugs with better CNS penetration, but they had complete clinical and MRI recovery after changing to therapy considering both CNS viral resistance and penetration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504362     DOI: 10.1089/AID.2011.0020

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  12 in total

1.  Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics.

Authors:  Sergio M de Almeida; Michelli F Oliveira; Antoine Chaillon; Indianara Rotta; Clea E Ribeiro; Ana Paula de Pereira; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-09-07       Impact factor: 2.643

2.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

3.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Authors:  Michael J Peluso; Francesca Ferretti; Julia Peterson; Evelyn Lee; Dietmar Fuchs; Antonio Boschini; Magnus Gisslén; Nancy Angoff; Richard W Price; Paola Cinque; Serena Spudich
Journal:  AIDS       Date:  2012-09-10       Impact factor: 4.177

4.  Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.

Authors:  Sergio M de Almeida; Indianara Rotta; Clea E Ribeiro; Michelli F Oliveira; Antoine Chaillon; Ana Paula de Pereira; Ana Paula Cunha; Marise Zonta; Joao França Bents; Sonia M Raboni; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2017-02-28       Impact factor: 2.643

Review 5.  Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Authors:  Francesca Ferretti; Magnus Gisslen; Paola Cinque; Richard W Price
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

6.  Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.

Authors:  José L Casado; Ana Marín; Ana Moreno; Verónica Iglesias; María J Perez-Elías; Santiago Moreno; Iñigo Corral
Journal:  J Neurovirol       Date:  2014-01-14       Impact factor: 2.643

7.  Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India.

Authors:  Atul K Patel; Ketan K Patel; Swati Gohel; Ambuj Kumar; Scott Letendre
Journal:  J Neurovirol       Date:  2018-04-24       Impact factor: 2.643

8.  Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.

Authors:  Shibani S Mukerji; Vikas Misra; David Lorenz; Anna M Cervantes-Arslanian; Jennifer Lyons; Spyridon Chalkias; Alysse Wurcel; Deirdre Burke; Nagagopal Venna; Susan Morgello; Igor J Koralnik; Dana Gabuzda
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

Review 9.  HIV and neurocognitive dysfunction.

Authors:  Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

10.  Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.

Authors:  Francesca Ferretti; Alba Bigoloni; Laura Passeri; Laura Galli; Valeria Longo; Simonetta Gerevini; Vincenzo Spagnuolo; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Dario Cattaneo; Giada Caramatti; Adriano Lazzarin; Paola Cinque; Antonella Castagna
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.